CN101326181A - 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物 - Google Patents

作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物 Download PDF

Info

Publication number
CN101326181A
CN101326181A CNA2006800371946A CN200680037194A CN101326181A CN 101326181 A CN101326181 A CN 101326181A CN A2006800371946 A CNA2006800371946 A CN A2006800371946A CN 200680037194 A CN200680037194 A CN 200680037194A CN 101326181 A CN101326181 A CN 101326181A
Authority
CN
China
Prior art keywords
pyridin
imidazo
pyridine
fluorine
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800371946A
Other languages
English (en)
Chinese (zh)
Inventor
伯奈特·米多·琼
席微亚·芳奎那·波
保罗·罗伯特·伊斯特伍德
荷西·艾瓜德·博世
阿瑞札祖·卡都斯·费格拉斯
艾尼斯·卡润可·莫鲁诺
约克伯·恭扎利兹·罗德瑞贵之
瑟吉欧·派瑞德斯·阿帕瑞奇欧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Publication of CN101326181A publication Critical patent/CN101326181A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2006800371946A 2005-10-06 2006-10-05 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物 Pending CN101326181A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200502433A ES2274712B1 (es) 2005-10-06 2005-10-06 Nuevos derivados imidazopiridina.
ESP200502433 2005-10-06

Publications (1)

Publication Number Publication Date
CN101326181A true CN101326181A (zh) 2008-12-17

Family

ID=36295447

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800371946A Pending CN101326181A (zh) 2005-10-06 2006-10-05 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物

Country Status (18)

Country Link
US (1) US7855202B2 (https=)
EP (1) EP1931666A1 (https=)
JP (1) JP2009510152A (https=)
KR (1) KR20080050475A (https=)
CN (1) CN101326181A (https=)
AR (1) AR055676A1 (https=)
AU (1) AU2006299028A1 (https=)
CA (1) CA2624879A1 (https=)
EC (1) ECSP088343A (https=)
ES (1) ES2274712B1 (https=)
IL (1) IL190336A0 (https=)
NO (1) NO20082121L (https=)
PE (1) PE20070706A1 (https=)
RU (1) RU2008117329A (https=)
TW (1) TW200800985A (https=)
UY (1) UY29836A1 (https=)
WO (1) WO2007039297A1 (https=)
ZA (1) ZA200802588B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103209981A (zh) * 2010-09-10 2013-07-17 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
CN107406425A (zh) * 2015-02-25 2017-11-28 帕罗生物制药有限公司 作为腺苷A2b受体拮抗剂和褪黑激素MT3受体的配体的2‑氨基吡啶的衍生物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2294066B9 (en) * 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
WO2010133534A1 (en) * 2009-05-19 2010-11-25 Cellzome Limited Bicyclic amino substituted compounds as pi3k inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
BR112012032766A2 (pt) 2010-06-30 2019-09-24 Gilead Sciences Inc uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
KR101913619B1 (ko) * 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
US9273034B2 (en) 2011-10-25 2016-03-01 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
JP2015515472A (ja) 2012-04-06 2015-05-28 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
RU2644558C2 (ru) * 2012-06-19 2018-02-13 Сановьон Фармасьютикалз Инк. Гетероарильные соединения и способы их применения
US9650376B2 (en) 2013-03-15 2017-05-16 Knopp Biosciences Llc Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
US11435340B2 (en) 2014-06-09 2022-09-06 Biometry Inc. Low cost test strip and method to measure analyte
SI3572405T1 (sl) 2014-09-12 2023-12-29 Biohaven Therapeutics Ltd. Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7
EP3487407B1 (en) 2016-07-19 2024-10-02 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
FI3562487T3 (fi) 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
US11312715B2 (en) 2017-09-28 2022-04-26 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Fused ring derivative as A2A receptor inhibitor
ES2992256T3 (es) * 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
CA3126224A1 (en) 2019-01-08 2020-07-16 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
WO2021095805A1 (ja) * 2019-11-13 2021-05-20 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤
BR112022008571A2 (pt) 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
KR0151816B1 (ko) * 1994-02-08 1998-10-15 강박광 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
ES2304797T3 (es) 1997-12-19 2008-10-16 Amgen Inc. Compuestos de piridina y piridazina sustituidos y su uso farmaceutico.
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
EP1208100B1 (en) 1999-08-31 2003-04-02 Vanderbilt University Selective antagonists of a2b adenosine receptors
CA2400206A1 (en) 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
JP4064671B2 (ja) 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
JP4251868B2 (ja) * 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4122216B2 (ja) 2000-09-19 2008-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＧＳＫ−３βタンパク質の特徴づけおよびその使用方法
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DE60206756T2 (de) * 2001-06-29 2006-07-13 CV Therapeutics, Inc., Palo Alto Purin derivate als a2b adenosin rezeptor antagonisten
TWI330183B (https=) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
DK1444233T3 (da) 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
EA200500005A1 (ru) 2002-06-12 2005-06-30 Байоджен Айдек Ма Инк. Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина
US20040067955A1 (en) 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
KR20120032574A (ko) 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
DE60322748D1 (de) 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
ES2557310T3 (es) 2003-08-25 2016-01-25 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
CA2544193C (en) 2003-10-31 2012-03-27 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2303776B1 (es) 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103209981A (zh) * 2010-09-10 2013-07-17 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
CN103209981B (zh) * 2010-09-10 2016-12-28 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
TWI567072B (zh) * 2010-09-10 2017-01-21 鹽野義製藥股份有限公司 具有ａｍｐｋ活性化作用之雜環稠合咪唑衍生物及其用途
CN107406425A (zh) * 2015-02-25 2017-11-28 帕罗生物制药有限公司 作为腺苷A2b受体拮抗剂和褪黑激素MT3受体的配体的2‑氨基吡啶的衍生物
CN107406425B (zh) * 2015-02-25 2020-06-26 帕罗生物制药有限公司 作为腺苷A2b受体拮抗剂和褪黑激素MT3受体的配体的2-氨基吡啶的衍生物

Also Published As

Publication number Publication date
ZA200802588B (en) 2009-09-30
AR055676A1 (es) 2007-08-29
WO2007039297A1 (en) 2007-04-12
ES2274712A1 (es) 2007-05-16
JP2009510152A (ja) 2009-03-12
RU2008117329A (ru) 2009-11-20
US7855202B2 (en) 2010-12-21
TW200800985A (en) 2008-01-01
UY29836A1 (es) 2007-04-30
US20080275038A1 (en) 2008-11-06
ES2274712B1 (es) 2008-03-01
IL190336A0 (en) 2009-09-22
KR20080050475A (ko) 2008-06-05
CA2624879A1 (en) 2007-04-12
PE20070706A1 (es) 2007-09-24
AU2006299028A1 (en) 2007-04-12
NO20082121L (no) 2008-07-07
EP1931666A1 (en) 2008-06-18
ECSP088343A (es) 2008-05-30

Similar Documents

Publication Publication Date Title
CN101326181A (zh) 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物
JP4650419B2 (ja) ピラジン誘導体およびその医薬的使用
CN1942469B (zh) 用作a28腺苷受体拮抗剂的稠合吡啶衍生物
CN101065377B (zh) 咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法
WO2023051753A1 (zh) 一种rock抑制剂的制备方法、其中间体及中间体的制备方法
TW200804338A (en) New compounds
ES2270715A1 (es) Nuevos derivados de pirazina.
CN101801931A (zh) 作为二氢乳清酸脱氢酶抑制剂的氮杂联苯胺基苯甲酸衍生物
EP2125804B1 (en) 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazo[4,5-b]pyridin-2-one derivatives useful as a2b adenosine receptor antagonists
JPS59141564A (ja) 新規ピリダジン誘導体，その製造方法及び該誘導体を含有する神経系治療剤
CN101495450A (zh) 用于治疗疼痛、胃肠道疾病和癌症的异吲哚衍生物
CN102633812B (zh) 噁唑酮并喹唑啉衍生物、制备方法及用途
JP2007532658A (ja) がんの治療方法
CN107721919B (zh) 苯基喹啉类trpv1拮抗剂及其制备方法和应用
AU2014372639A1 (en) Benzene sulfonamides as CCR9 inhibitors
CN103012381A (zh) 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
JP2019501126A5 (https=)
TW201249801A (en) 3-ureidoisoquinolin-8-yl derivatives
ES2234433B1 (es) 4-aminopirimidinas como antagonistas de receptores de adenosina.
CN109879820A (zh) 一种喹唑啉酮杂环化合物的合成方法
JPS601303B2 (ja) 新規オキシムエ−テル化合物およびその塩類
CN113999205B (zh) 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用
HK40070437B (zh) 一种含苯环的化合物及其应用
CN117362276A (zh) 一种原肌球蛋白受体激酶a抑制剂及其制备方法和应用
HK1146664B (en) P38 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081217